Document is current
Any future updates will be listed below
-
Authors
Mitra, Devarati
Ologun, Gabriel
Keung, Emily Z.
Goepfert, Ryan P.
Amaria, Rodabe N.
Ross, Merrick I.
Gershenwald, Jeffrey E.
Lucci, Anthony
Fisher, Sarah B.
Davies, Michael A.
Lee, Jeffrey E.
Bishop, Andrew J.
Farooqi, Ahsan S.
Wargo, Jennifer
Guadagnolo, B. Ashleigh
-
Funding
Funding for this research was provided by:
NIH Clinical Center (Cancer Center Support (Core) Grant CA016672 to (PI)
- License Information
-
More Information
Article History
Received: 29 December 2020
Accepted: 23 January 2021
First Online: 15 April 2021
Disclosure
: Dr. Gershenwald reported serving as a consultant and/or on the advisory board for Merck, Syndax, Castle Biosciences, Novartis, and Bristol Myers Squibb. Dr. Davies reported serving as a consultant to Roche/Genentech, Array, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex and Apexigen, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothyreon. Dr. Wargo reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb. J. Wargo serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, Ella Therapeutics, and Microbiome DX. Dr. Wargo also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol-Myers Squibb, and Novartis. No other disclosures were reported.
